Zacks rates Boston Scientific stock ‘buy’: 3 points

Zacks gave Boston Scientific stock a short term rating of “buy,” according to a Trade Calls report.

Advertisement

Here are three points:

1. Twelve Wall Street firms have rated the company’s stock as a “strong buy.”

2. Boston Scientific has a 52-week high of $23.35 and a 52-week low of $14.18.

3. The company’s market cap is $1.3 billion.

More articles on GI/endoscopy:
4 things to know about Healthmark’s Endoscope Cleaning Brush
5 most read GI/endoscopy stories: June 13 — June 17
Ohio Gastroenterology & Liver Institute incorporates HyGIeaCare Prep System: 3 points

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Birmingham (Ala.) Gastroenterology has opened a clinic in Jasper, Ala., expanding access to digestive health services in the region, the…

  • Premier Health Partners has acquired Dayton, Ohio-based Digestive Specialists, according to a notice posted on the website of law firm…

Advertisement

Comments are closed.